Literature DB >> 32281328

[Study on screening potential traditional Chinese medicines against 2019-nCoV based on Mpro and PLP].

Jing Ma1, Xiao-Qian Huo1, Xi Chen1, Wei-Xing Zhu2, Mei-Cun Yao3, Yan-Jiang Qiao1, Yan-Ling Zhang1.   

Abstract

With the rapid outbreak of COVID-19, traditional Chinese medicine(TCM) has been playing an active role against the epidemic. However, the screening of TCM is limited by the development cycle and laboratory conditions, which greatly limits the screening speed. This study established optimization docking models and virtual screening to discovery potential active herbs for the prevention and treatment of the novel coronavirus based on molecular docking technology. The crystal structures of 3 CL protease(Mpro) and papain-like protease(PLP) were obtained from PDB database and homologous modeling respectively, and were used to conduct virtual screening of TCMD 2009 database by CDOCKER program. The ingredients scored in the top 100 were selected respectively, and the candidate herbs were ranked by the numbers of hit molecules. Based on Mpro inhibitors screening, 12 322 potential active components were obtained, and the representative active components included aster pentapeptide A, ligustrazine, salvianolic acid B, etc., and Zingiberis Rhizoma Recens, Asteris Radix et Rhizoma, Notoginseng Radix et Rhizoma, Chuanxiong Rhizoma, Salviae Miltiorrhizae Radix et Rhizoma, Zingiberis Rhizoma, Dianthi Herba, Rhei Radix et Rhizoma, Cistanches Herba were obtained. While 11 294 potential active ingredients were obtained by PLP inhibitor screening, representative active ingredients included gingerketophenol, ginkgol alcohol, ferulic acid, etc., and Codonopsis Radix, Notopterygii Rhizoma et Radix, Zingiberis Rhizoma Recens, Ginkgo Semen, Chuanxiong Rhizoma, Trichosanthis Fructus, Paeoniae Radix Alba, Psoraleae Fructus, Sophorae Flavescentis Radix, Notoginseng Radix et Rhizoma, Angelicae Sinensis Radix were chosen. By combining the diagnosis and treatment scheme of Hunan province's and angiotensin converting enzyme 2(ACE2) inhibitors screening from literature, present study also discussed the rational application of candidate herbs to this epidemic situation. Trichosanthis Fructus obtained by PLP inhibitors screening and Fritillaria verticillata obtained by ACE2 inhibitors screening were parts of the Sangbei Zhisou Powder and Xiaoxianxiong Decoction, which might be applicable to the syndromes of cough and dyspnea. Rhei Radix et Rhizoma screened by Mpro and Trichosanthis Fructus screened by PLP were contained in Maxing Shigan Decoction and Xuanbai Chengqi Decoction, and could be applied to the syndromes of epidemic virus blocking lung. Mori Folium, Lonicerae Japonicae Flos and Forsythiae Fructus obtained by ACE2 inhibitors screening were included in the Sangju Decoction and Yinqiaosan, which might be applicable to the syndromes of warm pathogen attacking lung and cough and dyspnea. The results of this study are intended to provide a reference for the further development of traditional Chinese medicine to deal with the new epidemic.

Entities:  

Keywords:  2019-nCoV; 3CL hydrolase; angiotensin converting enzyme 2; molecular docking; papain-like protease; traditional Chinese medicine

Mesh:

Substances:

Year:  2020        PMID: 32281328     DOI: 10.19540/j.cnki.cjcmm.20200216.401

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  15 in total

Review 1.  Pain during and after coronavirus disease 2019: Chinese perspectives.

Authors:  Feng Jiang; Wan-Li Yang; Jia-Wei Wang; Zhen Zhu; Ceng Luo; Lars Arendt-Nielsen; Xue-Jun Song
Journal:  Pain Rep       Date:  2021-05-10

Review 2.  Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery.

Authors:  P Chellapandi; S Saranya
Journal:  Med Chem Res       Date:  2020-07-31       Impact factor: 2.351

Review 3.  Fight against novel coronavirus: A perspective of medicinal chemists.

Authors:  Sk Abdul Amin; Tarun Jha
Journal:  Eur J Med Chem       Date:  2020-06-12       Impact factor: 6.514

Review 4.  Anti-COVID-19 drug screening: Frontier concepts and core technologies.

Authors:  Hua Luo; Mingming Zhao; Dechao Tan; Chang Liu; Lin Yang; Ling Qiu; Yan Gao; Hua Yu
Journal:  Chin Med       Date:  2020-10-28       Impact factor: 5.455

Review 5.  Human coronaviruses and therapeutic drug discovery.

Authors:  Lan-Gui Song; Qing-Xing Xie; Hui-Lin Lao; Zhi-Yue Lv
Journal:  Infect Dis Poverty       Date:  2021-03-16       Impact factor: 4.520

Review 6.  SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches.

Authors:  Ramalingam Karthik Raja; Phuong Nguyen-Tri; Govindasamy Balasubramani; Arun Alagarsamy; Selcuk Hazir; Safa Ladhari; Alireza Saidi; Arivalagan Pugazhendhi; Arulandhu Anthoni Samy
Journal:  Appl Nanosci       Date:  2021-06-10       Impact factor: 3.869

7.  Scutellaria barbata D. Don Inhibits the Main Proteases (Mpro and TMPRSS2) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

Authors:  Sheng-Teng Huang; Yeh Chen; Wei-Chao Chang; Hsiao-Fan Chen; Hsiang-Chun Lai; Yu-Chun Lin; Wei-Jan Wang; Yu-Chuan Wang; Chia-Shin Yang; Shao-Chun Wang; Mien-Chie Hung
Journal:  Viruses       Date:  2021-05-02       Impact factor: 5.048

Review 8.  Herbal Medicine, Gut Microbiota, and COVID-19.

Authors:  Ziqi Chen; Yiwen Lv; Huachong Xu; Li Deng
Journal:  Front Pharmacol       Date:  2021-07-07       Impact factor: 5.988

Review 9.  An Update on Current Therapeutic Drugs Treating COVID-19.

Authors:  Renyi Wu; Lujing Wang; Hsiao-Chen Dina Kuo; Ahmad Shannar; Rebecca Peter; Pochung Jordan Chou; Shanyi Li; Rasika Hudlikar; Xia Liu; Zhigang Liu; George J Poiani; Louis Amorosa; Luigi Brunetti; Ah-Ng Kong
Journal:  Curr Pharmacol Rep       Date:  2020-05-11

10.  Molecular Docking and Dynamics Simulation Study of Hyrtios erectus Isolated Scalarane Sesterterpenes as Potential SARS-CoV-2 Dual Target Inhibitors.

Authors:  Sameh S Elhady; Reda F A Abdelhameed; Rania T Malatani; Abdulrahman M Alahdal; Hanin A Bogari; Ahmad J Almalki; Khadijah A Mohammad; Safwat A Ahmed; Amgad I M Khedr; Khaled M Darwish
Journal:  Biology (Basel)       Date:  2021-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.